AstraZeneca has entered an exclusive licence agreement with Alteogen involving the latter’s ALT-B4 platform technology.
Health Canada has granted approval for Biogen’s Skyclarys to treat Friedreich’s ataxia (FA) in individuals aged 16 years and above.